Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 15 August, 2007

XTL Biopharm Ltd

Notice of AGM / EGM


       Annual General Meeting ("AGM") and Extraordinary General Meeting        
                    ("EGM") Notices Posted to Shareholders                     

Valley Cottage, New York, August 15, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet medical needs, particularly neuropathic pain and hepatitis
C, today announced its has posted to shareholders a notice convening its AGM
and EGM. The AGM and EGM will take place at the Conference Room at the
Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot,
Israel 76100, at 4:00 p.m. Israel time, and 4:30pm Israel time, respectively,
on September 25, 2007.

At the AGM it is proposed that:

  * the annual reports for the year ended 31 December 2006 be received;
   
  * Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the
    Company's auditors and the fixing of their remuneration be authorized; and
   
  * Messrs Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
    as Directors of the Company.
   
At the EGM it is proposed that:

  * the registered share capital of the Company be increased from 300,000,000
    Ordinary Shares to 500,000,000 Ordinary Shares, NIS 0.02 nominal value
    each; and
   
  * the listing of the Company's Ordinary Shares on the Official List of the
    United Kingdom Listing Authority be cancelled.
   
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
 XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225
+972-8-930-4444


      

a d v e r t i s e m e n t